American journal of preventive cardiology最新文献

{"title":"PEGOZAFERMIN DEMONSTRATED ROBUST HISTOLOGIC IMPROVEMENT AND BENEFIT IN HEPATIC AND METABOLIC BIOMARKERS IN A 48-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL (ENLIVEN)","authors":"Cynthia L. Hartsfield PhD","doi":"10.1016/j.ajpc.2024.100807","DOIUrl":"10.1016/j.ajpc.2024.100807","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>Pharmacologic Therapy</div></div><div><h3>Background</h3><div>Metabolic dysfunction-associated steatohepatitis (MASH) is often associated with metabolic disorders such as obesity, metabolic syndrome, and/or diabetes. FGF21 analogs such as pegozafermin (PGZ) have direct effects on liver fibrosis as well as additional hepatic and extrahepatic benefits in patients with MASH. The Phase 2b ENLIVEN trial evaluated the efficacy and safety of PGZ given weekly (QW) or every two-weeks (Q2W) versus placebo in MASH patients with biopsy-proven F2/F3 fibrosis. The primary histology endpoints were assessed at week 24, followed by a 24-week blinded extension for a total of 48 weeks.</div></div><div><h3>Methods</h3><div>Patients were randomized to PGZ 15mg QW, 30mg QW, or 44mg Q2W or placebo for 24-weeks (histology-based primary endpoints). During the 24-week extension, patients continued their assigned treatment except for a subset of placebo patients who were re-randomized to receive PGZ 30mg QW. The full analysis set includes F2/F3 patients with NAFLD activity score (NAS) ≥4 at baseline (n=192).</div></div><div><h3>Results</h3><div>Both primary histological endpoints considered as reasonably likely surrogates of clinical outcome benefit - at least one stage of fibrosis improvement without worsening of MASH and MASH resolution without worsening of fibrosis - were achieved by a significantly higher proportion of patients treated with PGZ 30mg QW or 44 mg Q2W than placebo. PGZ treatment also improved liver fat content (MRI-PDFF), biomarkers of fibrosis (VCTE, ELF, PRO-C3) and liver injury (ALT, AST) as well as lipids and HgA1c at both 24 weeks and week 48. PGZ was generally safe and well tolerated with the most common treatment emergent adverse events (TEAEs) being mild/moderate nausea and diarrhea. No deaths occurred; six early terminations for TEAEs including one drug-related serious AE occurred.</div></div><div><h3>Conclusions</h3><div>Treatment with PGZ in MASH patients with F2/F3 fibrosis led to highly significant fibrosis regression and MASH resolution and to robust and sustained improvements in non-invasive biomarkers of liver fat and inflammation, fibrosis, and metabolic markers, with a favorable safety and tolerability profile. PGZ is the first therapy to achieve fibrosis regression and MASH resolution with a Q2W dosing regimen. The confirmatory Phase 3 program in MASH was recently initiated.</div><div>Please note that ENLIVEN 28-week data were presented at EASL 2023 and ENLIVEN 48-week data are accepted as an oral presentation for EASL 2024. This is the first abstract to include both data sets.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100807"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LIPID OPTIMIZATION AMONG PATIENTS WITH PERIPHERAL ARTERY DISEASE FOLLOWING REVASCULARIZATION IN A SINGLE-CENTER COHORT","authors":"Franck H. Azobou Tonleu MD","doi":"10.1016/j.ajpc.2024.100761","DOIUrl":"10.1016/j.ajpc.2024.100761","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>Peripheral Artery Disease</div></div><div><h3>Background</h3><div>Lipid management is a cornerstone of peripheral artery disease (PAD) treatment to reduce major adverse cardiac events. The 2018 ACC/AHA cholesterol guidelines recommended statins, ezetimibe, and/or PCSK9 inhibitors in selected patients to reach a low density lipoprotein cholesterol (LDL-c) &lt; 70 mg/dL.</div></div><div><h3>Methods</h3><div>The cohort included all patients who underwent their index limb revascularization for PAD between 01/01/2021 and 12/31/2022 at a large urban safety net hospital. The cohort was created using ICD-10 and CPT codes. Lipid lowering medications and LDL-c were abstracted at baseline (prior to index revascularization) and at one year post index discharge. For baseline labs, we used values either prior or during (if no prior value) index revascularization.</div></div><div><h3>Results</h3><div>The final cohort included 311 patients with 36% female, 49% Hispanic, 36% Black, and was 63 ± 10 years old. History of hypertension, hyperlipidemia, and type 2 diabetes were seen in 98%, 93%, and 79% of patients, respectively. Prior to revascularization, 78% of patients were on statins (53% high intensity, 22% moderate intensity), 7% on ezetimibe and no patients on PCSK-9i. By one year following revascularization, 94% were on statins (75% high intensity, 18% moderate intensity), 8% on ezetimibe, and no patients on PCSK-9i. Among 233 patients with baseline LDL-c, median was 81 mg/dL with 37% (86/233) with LDL-c &lt; 70 mg/dL. Following revascularization, 132 patients had repeat lipid panel with median LDL-c 65 mg/dL and 55% (73/132) of them with LDL-c &lt; 70 mg/dL.</div></div><div><h3>Conclusions</h3><div>LDL-c optimization is a cornerstone of PAD management, especially in a post-revascularization population. In this cohort, there was increase in both overall statin use and use of high intensity by 1 year following revascularization. However, only 42% of patients had repeat lipid panel following revascularization and the use of non-statin therapies remained low despite only half achieving targeted LDL-C. These findings highlight an important care gap, and revascularization as an important opportunity for lipid optimization. Clinician education and EHR (Electronic Health Record) interventions could be leveraged to improve outcomes in this population.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100761"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHARACTERISTICS AND RISK FACTORS OF YOUNG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN AN UNDERREPRESENTED COHORT: INSIGHTS FROM THE ALL OF US RESEARCH PROGRAM","authors":"Sara J. King MD","doi":"10.1016/j.ajpc.2024.100779","DOIUrl":"10.1016/j.ajpc.2024.100779","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD in Special Populations</div></div><div><h3>Background</h3><div>Recent research has found an increasing prevalence of atherosclerotic cardiovascular disease (ASCVD) in young adults (ages less than 50), however most studies were performed in predominantly White populations. We sought to evaluate the demographics, traditional medical risk factors, and social determinants of health of young ASCVD in the All of Us Research Program, an emerging national cohort study that seeks to investigate underrepresented populations.</div></div><div><h3>Methods</h3><div>We queried the All of Us database for individuals ages 20 to 49 years from 2017 to March, 2024 with completed data on demographics, income, education, and insurance. ASCVD was defined using ICD-10 codes for coronary artery disease (I20–I25) and stroke (I63, I65). Traditional medical risk factors were defined using ICD-10 codes and included type 2 diabetes mellitus (T2DM), hypertension, and hyperlipidemia. Tobacco use and obesity were defined using survey responses and body mass index, respectively. Unadjusted univariate and adjusted multivariate logistic regression models were performed with ASCVD as outcome and reported as odds ratios (OR) with 95% confidence intervals (CI).</div></div><div><h3>Results</h3><div>There were 90,313 individuals included, with 64.3% female, 50.2% non-white race, 24.5% Hispanic or Latino or other ethnicity, and 58.4% with annual income under $50,000. ASCVD was present in 2,219 (2.5%). In unadjusted univariate models, age (OR 1.10, CI 1.09-1.11), male gender (OR 1.16, CI 1.06-1.27), Black race (OR 1.46, CI 1.32-1.62), other race (OR 1.17, CI 1.04-1.30), annual incomes less than $25,000 (ORs 1.26-1.77, CIs 1.04-2.22), and traditional medical risk factors were associated with ASCVD. In adjusted multivariate logistic regression models, age, male gender, Black race, annual incomes less than $25,000, most education levels lower than college graduate, and traditional medical risk factors except obesity were associated with ASCVD, with hypertension showing the strongest association (Figure 1). Having medical insurance was associated with higher odds of ASCVD.</div></div><div><h3>Conclusions</h3><div>Several traditionally underrepresented groups including Black race, low annual income (less than $25,000), and education levels lower than college graduate were associated with ASCVD at a young age.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100779"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142423022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ELEVATED BIOMARKERS AS CRP, BNP AND/OR MICROALBUMIN IN ASYMPTOMATIC OBESE SUBJECTS MIGHT BE CLUE FOR PERIVASCULAR/EPICARDIAL ADIPOSITY WHICH MANDATES FURTHER CARDIOVASCULAR EVALUATION.","authors":"Antonella Sabatini","doi":"10.1016/j.ajpc.2024.100769","DOIUrl":"10.1016/j.ajpc.2024.100769","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>Novel Biomarkers</div></div><div><h3>Background</h3><div>Perivascular/cardio-adiposity have been reported to be cardiovascular risk markers. Purpose: To assess whether elevated biomarkers such as CRP and BNP and/or microalbumin in asymptomatic obese subjects are associated with elevated epicardial fat volume/perivascular adiposity contributing to structural and functional abnormalities such as abnormally elevated C2, abnormal blood pressure post exercise, abnormal CIMT and elevated calcium score.</div></div><div><h3>Methods</h3><div>330 asymptomatic obese subjects were screened for cardiovascular risk assessment using the Early Cardiovascular Disease Risk Scoring System (ESCVDRS) known as Rasmussen Risk Score (RRS), previously reported. The ESCVDRS includes 7 vascular and 3 cardiac tests. Among the additional test, CRP, proBNP, microalbumin were also measured. Coronary calcium score and epicardial fat volume was measured utilizing cardiac CT Siemens Somatom Definition Dual source CT scanner 64x2. Out of the 330s subjects, 55 showing objective high coronary calcium score were divided into 2 groups according to epicardial fat volume levels: Group A, 33 subjects with high epicardial fat volume and high calcium score; Group B, 22 subjects with high calcium score but normal epicardial fat volume.</div></div><div><h3>Results</h3><div>Results are shown on table below. Subjects with elevated EFV have elevated CAC and biomarkers in addition to structural and functional abnormalities.</div><div>As for the early screening for early cardiovascular subclinical atherosclerosis, mandating early detection and intervention, subjects with elevated epicardial fat volume have significantly elevated coronary calcium score associated with significant elevation in biomarker such as BNP, CRP and microalbumin in addition to structural and functional abnormalities. In addition, abnormal rise in blood pressure post exercise. It is of interest to note that subjects with elevated epicardial fat volume have more ECG abnormalities as compared with subject was normal epicardial fat volume.</div></div><div><h3>Conclusions</h3><div><ul><li><span>1.</span><span><div>Abnormal biomarkers such as CRP, BNP and/or microalbumin even in asymptomatic subjects might be the clue for abnormally elevated epicardial fat volume which is a novel risk marker associated with significant structural and functional abnormalities.</div></span></li><li><span>2.</span><span><div>Elevated biomarkers mandate early screening for cardiovascular structural and functional abnormalities, particularly excess epicardial fat volume, implementing treatment to avoid any future complications. Early detection to protect.</div></span></li></ul></div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100769"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RELATIONSHIP BETWEEN RED CELL DISTRIBUTION WIDTH AND SUBCLINICAL MYOCARDIAL INJURY IN THE GENERAL POPULATION","authors":"Sneha Chebrolu MD","doi":"10.1016/j.ajpc.2024.100738","DOIUrl":"10.1016/j.ajpc.2024.100738","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Factors</div></div><div><h3>Background</h3><div>Red cell distribution width (RDW) is a marker of anisocytosis, defined as heterogeneity in red blood cell (RBC) size. Elevated RDW has been associated with cardiovascular disease (CVD) and mortality, but the relationship with subclinical CVD is not well established.</div></div><div><h3>Methods</h3><div>We examined the cross-sectional associations between RDW and subclinical myocardial injury (SCMI), as a measure of subclinical CVD, using the National Health and Nutrition Examination Survey (NHANES-III). We considered participants who had complete electrocardiogram and RDW data available. Participants who were without CVD or anemia (hemoglobin &lt;14 males and &lt;12 for females) at the time of enrollment were included. RDW was measured using the Coulter automated hematology analyzer, which counts and sizes RBCs using a fluid suspension technique. NHANES-III reports RDW as a coefficient of variation. We defined RDW <strong>≤</strong> 14.5 as normal and RDW &gt;14.5 as high. SCMI was defined as a cardiac infarction injury score (CIIS) ≥10 using ECG metrics. Multivariate logistic regression was used to investigate the correlation between RDW (high vs. normal and across tertiles) and SCMI.</div></div><div><h3>Results</h3><div>This analysis included 5,716 participants (age 58.8±13.0 years, female 56.7%, White 52.2%). The adjusted odds ratio (OR [95% CI]) of SCMI associated with each one unit increase in RDW was 1.16(1.08-1.24; p&lt;0.001). Participants with RDW&gt;14.5 had 39% greater odds of SCMI than participants with RDW ≤14.5 (p=0.007). Participants in tertile 2 and tertile 3 had a 19% and 43% greater odds of SCMI, respectively, compared to participants in tertile 1 (Table).</div></div><div><h3>Conclusions</h3><div>Our analysis found that increased RDW is associated with SCMI. Further research is warranted to elucidate the mechanism by which high RDW contributes to subclinical CVD.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100738"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SILENT CARDIOVASCULAR THREATS: DEPRESSION AND MORBID OBESITY AMONGST DIABETIC WOMEN","authors":"Sunaina Addanki BS","doi":"10.1016/j.ajpc.2024.100744","DOIUrl":"10.1016/j.ajpc.2024.100744","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>CVD Prevention – Primary and Secondary</div></div><div><h3>Case Presentation</h3><div>We present the case of a 72-year-old female with morbid obesity with a BMI of 37.8, uncontrolled diabetes, hypertension, and hyperlipidemia, who was seen in her primary care physician's office for a routine follow-up where she mentioned symptoms of depression, insomnia, and fatigue. The patient denied chest pain, worsening shortness of breath, or any lower extremity edema. Notably, the patient's last echocardiogram in 2021 revealed an ejection fraction of 55-60%. Additionally, no abnormalities were noted on her nuclear stress test in 2021. While managing her depressive symptoms, she presented to the emergency department with aphasia due to an acute left frontal cerebral vascular accident requiring thrombectomy. Post-procedure echocardiography revealed a left ventricular thrombus and an ejection fraction of 8%, prompting cardiac catheterization which revealed severe diffuse obstructive cardiac atherosclerotic disease. The patient developed cardiogenic shock with acute heart failure with reduced ejection fraction and ischemic cardiomyopathy stage D. This condition rendered her myocardium nonviable. Aggressive diuresis was initiated with milrinone and dobutamine therapy. Subsequently, the patient suffered from shock with severe hypotension due to vasopressor treatment, shock liver, and pre-renal azotemia, necessitating careful management of these complications.</div></div><div><h3>Background</h3><div>There is an intricate relationship between depression, cardiovascular disease, and silent myocardial infarctions. Failure to recognize the overlap between depression-related fatigue and cardiovascular disease can result in underdiagnosis and mismanagement. The shared symptoms coupled with inflammation as pathophysiological mechanism for these conditions, bridges the link between depression and cardiovascular health. Additionally, the prevalence of silent myocardial infarctions in morbidly obese diabetic women may obscure the presentation of a MI, leading to delayed diagnosis and increased morbidity and mortality.</div></div><div><h3>Conclusions</h3><div>This case emphasizes the need to raise awareness regarding two topics: the interrelation between depression and cardiovascular disease, along with the complexities of silent myocardial infarctions (MI) in morbidly obese diabetic women. Future directions should include developing targeted screening protocols with multidisciplinary approaches involving primary care physicians, endocrinologists, psychiatrists, cardiologists. Protocols that assess depression, fatigue, glycemic control, and weight management in patients with elevated cardiovascular risk factors will address the burden of depression, cardiovascular disease, diabetes, and obesity.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100744"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFECTS OF CPAP USE IN PREVENTING ATRIAL FIBRILLATION RECURRENCE POST-ABLATION IN OSA PATIENTS","authors":"Sumeet S. Mutti MD","doi":"10.1016/j.ajpc.2024.100732","DOIUrl":"10.1016/j.ajpc.2024.100732","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Factors</div></div><div><h3>Background</h3><div>With the escalating global prevalence of atrial fibrillation (AF) and its recognized link to obstructive sleep apnea (OSA), this study focuses on assessing the efficacy of continuous positive airway pressure (CPAP) therapy in reducing AF recurrence following catheter-based pulmonary vein isolation.</div></div><div><h3>Methods</h3><div>Following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive systematic review and meta-analysis. The search was limited to English-language journal articles published from 2010 up to June 2023. Our search spanned various databases, targeting studies reporting AF recurrence post-ablation exclusively in patients diagnosed with OSA with AHI &gt; five. After stringent selection criteria, we applied the Mantel-Haenszel method for analysis, using the pooled relative risk (RR) as the core outcome measure.</div></div><div><h3>Results</h3><div>Data from Five studies with 1023 in total patients from three cohort studies and two intention-to-treat Randomized Control Trial was extracted. Both common effect and random effects models consistently demonstrated a substantial reduction in AF recurrence post-ablation attributed to CPAP intervention, yielding pooled RRs of 0.6075 and 0.6101, respectively. Patients who used CPAP showed 39.1% relative risk reduction (in the random effect model) of AF recurrence post-ablation compared to those who did not use CPAP. Heterogeneity analysis indicated moderate variability, and Egger's test suggested minimal risk of publication bias.</div></div><div><h3>Conclusions</h3><div>The findings highlight the potential of CPAP therapy in significantly curtailing AF recurrence among individuals with OSA, particularly in the context of post-ablation scenarios. CPAP's influence may extend to rectifying atrial structural and electrical remodeling, translating into a tangible decrease in AF recurrence rates.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100732"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A VIRTUAL WEIGHT MANAGEMENT PROGRAM IS ASSOCIATED WITH WEIGHT LOSS, REDUCED WAIST CIRCUMFERENCE, AND INCREASED SATISFACTION FOR WOMEN WITH OBESITY AT RISK FOR CARDIOVASCULAR DISEASE","authors":"Simona Campa DNP, ACNP-BC","doi":"10.1016/j.ajpc.2024.100733","DOIUrl":"10.1016/j.ajpc.2024.100733","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>Obesity</div></div><div><h3>Background</h3><div>Obesity is a chronic, progressive, and relapsing health condition that increases cardiovascular disease (CVD) risk, yet management is challenging, and weight loss is typically not sustained. We hypothesized a Nurse Practitioner (NP)-led virtual weight management program will result in weight loss, reduced waist circumference (WC), and increased satisfaction for obese women at risk for CVD.</div></div><div><h3>Methods</h3><div>Women enrolled in an observational, single center study in the outpatient cardiology clinics in a large academic medical center in Southern California. Women with a BMI over 30 kg/m2 and at least one CVD risk factor were eligible. Measures included a digital-based weight-tracking application, a smart scale, a smart tape measure, and a satisfaction with the program survey. Thirty women were followed for eight weeks between January-March 2023. Each woman met twice on a virtual platform to receive dietary counseling using motivational interviewing and to establish weight goals with the NP. The women received booster texts every two weeks to submit weights and WC. Paired t-tests were used to compare mean scores pre-and post-intervention.</div></div><div><h3>Results</h3><div>Thirty women enrolled and 26 completed the program. Mean age was 54.0±13.4 years, and White (n=19, 73.2 %). There was a significant reduction in mean weight (6.4 lbs.±6.6 lbs; p &lt; 0.001; 3.2 %±2.9 body weight) and WC (3.0 in.±1.6; p &lt; 0.001) (Figure). Twenty-two women lost weight and reduced their BMI. Ninety two percent of women (n=24) were satisfied with the program.</div></div><div><h3>Conclusions</h3><div>This NP-led virtual weight management program resulted in the majority of women significantly reduce their weight and WC using novel self-monitoring technology in addition to behavioral counseling on lifestyle modifications. Utilizing smart scales for digital self-monitoring has the potential to offer a promising strategy for obese women at risk for CVD to achieve sustained weight loss.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100733"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MONOTHERAPY EZETIMIBE-INDUCED RHABDOMYOLYSIS","authors":"Niharika Baviriseaty MD","doi":"10.1016/j.ajpc.2024.100777","DOIUrl":"10.1016/j.ajpc.2024.100777","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>Pharmacologic Therapy</div></div><div><h3>Case Presentation</h3><div>A 62-year-old female with a past medical history of type one diabetes, coronary artery disease, hyperlipidemia, and previous statin-induced rhabdomyolysis presented with one month of worsening muscle pain. Two months ago, she was started on monotherapy ezetimibe 10mg daily. On presentation, labs were notable for creatine kinase of 2509 U/L (normal: 51-296 U/L) (figure 1), creatinine of 1.5 mg/dL with baseline 0.9 mg/dL (normal 0.6-1.0 mg/dL), and urinalysis with myoglobinuria. IV fluids and pain medications were started. Given normal autoimmune panel and thyroid labs with no other precipitating events, the decision was made to discontinue ezetimibe. Creatine kinase trended to normal levels of 186 U/L (figure 1) within 3 days of discontinuation. Her myalgias improved and she was started on a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor outpatient.</div></div><div><h3>Background</h3><div>Ezetimibe is often used in the setting of statin-induced myopathy. We report a rare case of monotherapy ezetimibe-induced rhabdomyolysis in a patient with previous history of rhabdomyolysis due to statins.</div></div><div><h3>Conclusions</h3><div>Previous cases in literature have reported combined ezetimibe/statin induced myopathy or rhabdomyolysis. However, monotherapy ezetimibe should also be considered in the differential for patients presenting with myopathy or rhabdomyolysis. More research needs to be performed in patients with previous myopathy due to statins to elucidate if they are at increased risk with ezetimibe as well. In these patients, PCSK9 inhibitors should be considered as an alternative treatment option.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100777"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CORRELATION BETWEEN THE AMERICAN HEART ASSOCIATION LIFE'S SIMPLE 7 AND LIFE'S ESSENTIAL 8 SCORES IN A COHORT OF AFRICAN AMERICAN ADULTS","authors":"Mathias Lalika MD, MPH","doi":"10.1016/j.ajpc.2024.100811","DOIUrl":"10.1016/j.ajpc.2024.100811","url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Factors</div></div><div><h3>Background</h3><div>The American Heart Association (AHA) recently updated its Life's Simple 7 (LS7) cardiovascular health metric to Life's Essential 8 (LE8) by including sleep health and recognition of psychosocial influences on cardiovascular health. African American adults face psychosocial and structural factors affecting sleep and the achievement of optimal cardiovascular health; thus, we examined the correlation between LS7 and LE8 scores in a community sample of African American adults.</div></div><div><h3>Methods</h3><div>Demographic, behavioral (e.g., diet), and clinical (e.g., lipids) measures were collected from African American adults at 16 churches in Minnesota as part of a randomized controlled trial (FAITH! Trial) and an accompanying ancillary study (Heart Health+). We computed LS7 (range: 0-14) and LE8 scores (range: 0-100), indicating low to high cardiovascular health, as per AHA recommendations. Pearson correlation was used to assess the linear correlation between the two cardiovascular health scores.</div></div><div><h3>Results</h3><div>Participants (N=58) were predominantly female (67%), with a mean age of 54 (SD 12) years and high cardiometabolic risk (93% had overweight/obesity) (Table 1). Mean composite LS7 and LE8 scores were 6.7 [1.9] and 56.9 [11.6], respectively. Mean LE8 scores were highest for tobacco/nicotine exposure (84.1 [24.2]) and lowest for diet (30.3 [12.4]). LE8 was strongly correlated with LS7 (r=0.84, p&lt;0.001).</div></div><div><h3>Conclusions</h3><div>In African American adults, the new LE8 score correlates well with LS7, a well-established metric for measuring cardiovascular health. LE8 score may aid in monitoring tailored interventions that target psychosocial factors to enhance cardiovascular health in this population.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100811"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}